Compare Ecolab Inc. (ECL) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ecolab Inc. vs Revvity Inc — how do they compare? Ecolab Inc. trades at $281.36 (market cap $78.97B), while Revvity Inc trades at $152.05 (market cap $16.98B). The key difference: Ecolab Inc. is far larger — about 4.7× Revvity Inc's market cap, and Ecolab Inc. pays the higher dividend (1.04%). Which is the better fit depends on your goals — on Pluang, investors hold Ecolab Inc. for 90 Days and Revvity Inc for 12 Days on average.
| ECL | RVTY | |
|---|---|---|
Market Cap | $78.97B | $16.98B |
Volume | 974,947 | 1,456,900 |
Sector | Basic Materials | Health |
52-Week High | $308.35 | $157.36 |
52-Week Low | $245.73 | $82.26 |
Typical Hold Time | 90 Days | 12 Days |
Enterprise Value | $87.75B | $19.30B |
Dividend Yield | 1.04% | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ECL trades at $278.10, down 0.97% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported $16.08B in 2025 revenue, with a net income margin of 12.57% and strong profitability metrics. Recent news highlights its dividend aristocrat status and growth in high-tech segments, while institutional buying and insider purchases reflect confidence.
Outlook remains positive with a consensus price target of $326.38, implying 17% upside, supported by analyst buy ratings (78%). Risks include elevated valuation multiples and increased debt from the CoolIT acquisition. Earnings growth in high-tech and digital segments is a key catalyst, though cost fluctuations pose headwinds.
RVTY trades at $153.60, up 0.2% today and near its 52-week high of $158.28 (Defense World, 2026-10-01). The stock shows a bullish technical trend with strong moving average signals and has beaten earnings estimates for three consecutive quarters. Recent developments include the launch of a CE-IVDR-certified T1D screening kit in Europe (Business Wire, 2026-09-24) and the acquisition of Human Cell Design to expand metabolic disease research tools (Business Wire, 2026-09-09).
The outlook is positive, supported by earnings momentum, strategic acquisitions, and analyst optimism. However, the stock trades at a premium valuation with a P/E of 73.15, and near-term risks include margin pressures in China and rich valuation limiting upside beyond consensus targets. Revenue stability but slight profit margin compression in 2026 warrants monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ecolab Inc.
Ecolab produces and markets cleaning and sanitation products for the hospitality, healthcare, and industrial markets. The firm is the global market share leader in this category with a wide array of products and services, including dish and laundry washing systems, pest control, and infection control products. The company has a strong hold on the U.S. market and is looking to increase its profitability abroad. Additionally, Ecolab serves customers in water, manufacturing, and life sciences end markets, selling customized solutions.
Read more on ECL →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
